INSUBCONTINENT EXCLUSIVE:
Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy
have been researching stem cells for humans for decades
says could receive FDA approval by early 2026.The field has shown some encouraging early results
Studies on dogs with arthritis showed improvements in pain and mobility, with some benefits lasting up to two years
ready-to-use cells from donor animals, even if they are a different species.Investors clearly see potential here
The funding round was led by existing backer Digitalis Ventures, with participation from NovaQuest Capital Management, which previously
invested in the first FDA-approved human stem cell therapy
The company has an interesting backstory
Hirschhorn passed away in 2021; Gallant is now led by Linda Black, who joined as its president and chief scientific officer from nearly the
Gallant has now raised at least $44 million altogether from investors.
